u/blunt_coldbox_2024

Is that baseline drawn by the software or by hand?

Did you run a blank between injections?

A goal weight chosen before starting is a prediction made with the least information you will ever have. Revising it is ordinary rather than a failure.

Gently disagree with the framing — that is not a plateau, that is a month. They are different things.

Insulin resistance is a common feature in PCOS, which is why the metabolic conversation overlaps so heavily with this board. A diagnosis and a finding are still different things and the distinction matters for what the evidence says.

Reading a trace posted here, in the order I actually look at things.

Axes first — if the wavelength and the time axis are not labelled, I stop. Then the baseline: where has it been drawn, and does the drawing absorb anything. Then peak shape: fronting, tailing, a shoulder that never resolves. Then the blank, if one was run, for carryover.

Only after all of that do I look at the percentage, and by then I usually know how much weight it deserves. The number is the last thing on the page and the first thing everybody argues about, which is exactly backwards.

write the concentration on the vial, you will thank yourself

a plateau is not a failure and it is not a personality

Agreed — somebody is at exactly the point you were at, reading this, and it will land differently for them than any success story.

The pattern almost everyone here describes, written out once so it can be linked.

A step up is followed by a rough window — commonly sulphur burps arriving the day after the shot and easing by day four, worst in the first fortnight, then flattening out. At a stable dose it usually settles further. Constipation and fatigue tend to track intake and fluid rather than the compound directly, which is why the unglamorous answers work.

What sits outside that pattern: severe pain, symptoms that appear from nowhere weeks into a stable dose, or anything getting worse rather than better over a month. None of that is a board question and none of us can answer it for you.

Where to look instead of asking, which will nearly always be faster.

The national shortage database is public, searchable and carries expected resolution dates. The subsidy criteria for each indication are published. Your pharmacist can check wholesaler availability in a few minutes, which is a different question from what is on the shelf.

Between those three, most questions on this board are answerable in half an hour with primary sources. The board is genuinely useful for experience, pricing comparison and the parts that are not written down anywhere — it is a poor substitute for a document that exists.

The directory deliberately separates "we have nothing on this name" from "this went badly". Collapsing the two is how boards like this generate false certainty.

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

mateusz_mensah is right about the escalation being the variable. It explains most of the difficult reports here.

not approved anywhere, which is the single most important fact in this board

Pharmacy-level availability and national supply are different questions: a pharmacy can be out while the wholesaler is not, and the pharmacist can check in minutes.

Held the dose for an extra six weeks instead of stepping. The early fullness settled and I lost the same amount anyway.

The thing that surprised me was how much of the discussion here is inference rather than measurement.

screenshots are not evidence, dates and documents are

I would be careful here. "Everyone gets this" is not true, and it makes the people who get something unusual assume they are fine when they should be asking.

What dates are we talking about — order, payment, last contact?

Adding the practical version: buy small from anyone new, test it, then decide.

Small fix — the name you are describing is in the wider-market table with almost nothing on file, not in the documented twenty.

Have you checked the shortage database directly?

rohan_steiner is right about the timing.

Adding to this — holding the dose rather than stepping is the option people forget they have.

Right, and writing the concentration on the vial is the single best habit anyone here can start with.

read the wiki first, then ask anyway

Retention time shifted 0.4 minutes and I assumed the worst. It was the column temperature.

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

reflux for the first eight days after each step, then nothing, every single time. Predictable enough that I started planning my week around it.

The pattern almost everyone here describes, written out once so it can be linked.

A step up is followed by a rough window — commonly constipation arriving the day after the shot and easing by day four, worst in the first fortnight, then flattening out. At a stable dose it usually settles further. Constipation and fatigue tend to track intake and fluid rather than the compound directly, which is why the unglamorous answers work.

What sits outside that pattern: severe pain, symptoms that appear from nowhere weeks into a stable dose, or anything getting worse rather than better over a month. None of that is a board question and none of us can answer it for you.

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

Telogen shedding follows a period of significant weight change rather than a specific compound, and it resolves.

nobody gets judged here, that is the entire premise

What did the pharmacy quote for the private price?

Disagree — that is a general claim about absorption and the specific question needs a pharmacist rather than a board.

The reflux profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

That is a pharmacy-level stock issue rather than a national supply issue. They feel identical and are not.

A token symbol identifies an asset, not a network. The same symbol commonly exists on several chains with incompatible address formats, and sending across that boundary is generally unrecoverable.

Correction: that is a known effect of reduced intake rather than a direct drug effect. The distinction matters because the fix is different.

Nothing here is medical advice, and the honest version of most of these posts is that they describe consequences rather than causes.